Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Part of paid clinical trials in Irving, Texas.

Sponsor
ArriVent BioPharma, Inc.
Study ID
NCT07755436
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ARR-002 — DRUG
    ARR-002 will be administrated as specified in the protocol.

Study Details

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

Key Dates

First listed
Aug 10, 2026
Start date
Jul 23, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2027
Completion
May 31, 2029

Study Design

Enrollment
180 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: ARR-002

Primary Outcome Measure

Treatment-Emergent Adverse Event (TEAE) [ Time Frame: Baseline to 30 days after the last dose of study treatment ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
NEXT OncologyIrvingTexas75039-
NEXT OncologyFairfaxVirginia22031-

Find similar trials in Irving, TX

Nationwide
Endometrial cancer trialsOvarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials
By condition
Endometrial cancerOvarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
NEXT Oncology· Irving, TXNEXT Oncology· Fairfax, VA

Related Studies